Literature DB >> 23954450

Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.

Betina Durovni1, Valeria Saraceni, Lawrence H Moulton, Antonio G Pacheco, Solange C Cavalcante, Bonnie S King, Silvia Cohn, Anne Efron, Richard E Chaisson, Jonathan E Golub.   

Abstract

BACKGROUND: Preventive therapy for tuberculosis in patients with HIV is effective, but it has not been widely implemented in moderate or high-burden settings. We assessed the effect of widespread use of isoniazid preventive therapy on rates of tuberculosis and death in people with HIV in Brazil.
METHODS: We did a stepped wedge, cluster-randomised trial with patients actively enrolled in 29 HIV clinics in Rio de Janeiro. Clinic staff were trained in tuberculosis screening, use of tuberculin skin tests, and use of isoniazid preventive therapy. Clinics were randomly allocated a date to begin the intervention period, with two clinics beginning the intervention every 2 months starting from Sept 1, 2005. The primary outcome was tuberculosis incidence alone or combined with death in the control versus intervention periods until Aug 31, 2009. This trial is registered at ClinicalTrials.gov, number NCT00107887.
RESULTS: Of 17,413 patients in the cohort, 12,816 were eligible for the intervention. Overall, there were 475 tuberculosis cases and 838 deaths. The intervention increased the rate of patients receiving skin tests from 19 per 100 person-years to 59 per 100 person-years, and from 36 per 100 person-years to 144 per 100 person-years for those eligible for isoniazid preventive therapy. In the control period, 221 cases of tuberculosis were diagnosed (1.31 per 100 person-years) compared with 254 (1.10 per 100 person-years) in the intervention period (unadjusted hazard ratio [HR] 0.87; 95% CI 0.69-1.10). Rates of tuberculosis incidence or death were 3.64 and 3.04 per 100 person-years, respectively (0.76; 95% CI 0.66-0.87). When adjusted for age, sex, entry CD4 count, and use of antiretroviral therapy, the HR for tuberculosis was 0.73 (95% CI 0.54-0.99) and for tuberculosis or death was 0.69 (0.57-0.83).
INTERPRETATION: Operational training aimed at increasing tuberculosis screening, provision of tuberculin skin tests, and use of isoniazid preventive therapy in Brazilian HIV clinics significantly reduced incident tuberculosis and death. Thus, scale-up of preventive therapy for HIV-infected patients in settings of moderate tuberculosis incidence is achievable and should be widely implemented in Brazil and elsewhere. FUNDING: Bill & Melinda Gates Foundation and the National Institutes of Health.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23954450      PMCID: PMC3899698          DOI: 10.1016/S1473-3099(13)70187-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  18 in total

1.  Balance in cluster randomized trials.

Authors:  G M Raab; I Butcher
Journal:  Stat Med       Date:  2001-02-15       Impact factor: 2.373

2.  The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.

Authors:  Betina Durovni; Solange C Cavalcante; Valeria Saraceni; Vitoria Vellozo; Giselle Israel; Bonnie S King; Silvia Cohn; Anne Efron; Antonio G Pacheco; Lawrence H Moulton; Richard E Chaisson; Jonathan E Golub
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

3.  Integration of antiretroviral therapy with tuberculosis treatment.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew L Gray; Tanuja Gengiah; Santhanalakshmi Gengiah; Anushka Naidoo; Niraksha Jithoo; Gonasagrie Nair; Wafaa M El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

Review 4.  III Brazilian Thoracic Association Guidelines on tuberculosis.

Authors:  Marcus Barreto Conde; Fernando Augusto Fiuza de Melo; Ana Maria Campos Marques; Ninarosa Calzavara Cardoso; Valeria Goes Ferreira Pinheiro; Paulo de Tarso Roth Dalcin; Almério Machado Junior; Antonio Carlos Moreira Lemos; Antônio Ruffino Netto; Betina Durovni; Clemax Couto Sant'Anna; Dinalva Lima; Domenico Capone; Draurio Barreira; Eliana Dias Matos; Fernanda Carvalho de Queiroz Mello; Fernando Cezar David; Giovanni Marsico; Jorge Barros Afiune; José Roberto Lapa e Silva; Leda Fátima Jamal; Maria Alice da Silva Telles; Mário Hiroyuki Hirata; Margareth Pretti Dalcolmo; Marcelo Fouad Rabahi; Michelle Cailleaux-Cesar; Moises Palaci; Nelson Morrone; Renata Leborato Guerra; Reynaldo Dietze; Silvana Spíndola de Miranda; Solange Cesar Cavalcante; Susie Andries Nogueira; Tatiana Senna Galvão Nonato; Terezinha Martire; Vera Maria Nader Galesi; Valdério do Valle Dettoni
Journal:  J Bras Pneumol       Date:  2009-10       Impact factor: 2.624

5.  New regimens to prevent tuberculosis in adults with HIV infection.

Authors:  Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

6.  Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.

Authors:  G W Comstock; C Baum; D E Snider
Journal:  Am Rev Respir Dis       Date:  1979-05

7.  Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention.

Authors:  Lawrence H Moulton; Jonathan E Golub; Betina Durovni; Solange C Cavalcante; Antonio G Pacheco; Valeria Saraceni; Bonnie King; Richard E Chaisson
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

8.  The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.

Authors:  Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

9.  Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.

Authors:  Jonathan E Golub; Paul Pronyk; Lerato Mohapi; Nkeko Thsabangu; Mosa Moshabela; Helen Struthers; Glenda E Gray; James A McIntyre; Richard E Chaisson; Neil A Martinson
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

Review 10.  Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.

Authors:  Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich
Journal:  PLoS Med       Date:  2012-07-24       Impact factor: 11.069

View more
  54 in total

1.  Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.

Authors:  Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson
Journal:  Clin Infect Dis       Date:  2014-11-02       Impact factor: 9.079

2.  Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped.

Authors:  Faiz Ahmad Khan; Sabine Verkuijl; Andrew Parrish; Fadzai Chikwava; Raphael Ntumy; Wafaa El-Sadr; Andrea A Howard
Journal:  AIDS       Date:  2014-06-19       Impact factor: 4.177

3.  Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.

Authors:  David W Dowdy; Jonathan E Golub; Valeria Saraceni; Lawrence H Moulton; Solange C Cavalcante; Silvia Cohn; Antonio G Pacheco; Richard E Chaisson; Betina Durovni
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

Review 4.  Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Authors:  Nicole Salazar-Austin; David W Dowdy; Richard E Chaisson; Jonathan E Golub
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

5.  Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.

Authors:  Timothy R Sterling; Nigel A Scott; Jose M Miro; Guilherme Calvet; Alberto La Rosa; Rosa Infante; Michael P Chen; Debra A Benator; Fred Gordin; Constance A Benson; Richard E Chaisson; M Elsa Villarino
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

Review 6.  Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection.

Authors:  Molebogeng X Rangaka; Solange C Cavalcante; Ben J Marais; Sok Thim; Neil A Martinson; Soumya Swaminathan; Richard E Chaisson
Journal:  Lancet       Date:  2015-10-26       Impact factor: 79.321

Review 7.  Transforming the fight against tuberculosis: targeting catalysts of transmission.

Authors:  David W Dowdy; Andrew S Azman; Emily A Kendall; Barun Mathema
Journal:  Clin Infect Dis       Date:  2014-06-30       Impact factor: 9.079

8.  Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach.

Authors:  Gabriel Chamie; Bonnie Wandera; Carina Marquez; Midori Kato-Maeda; Moses R Kamya; Diane V Havlir; Edwin D Charlebois
Journal:  Trop Med Int Health       Date:  2015-02-04       Impact factor: 2.622

9.  Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort.

Authors:  Valeria Saraceni; Silvia Cohn; Solange C Cavalcante; Antonio G F Pacheco; Lawrence H Moulton; Richard E Chaisson; Betina Durovni; Jonathan E Golub
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

10.  Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.

Authors:  Tyler Smith; Taraz Samandari; Taiwo Abimbola; Barbara Marston; Nalinee Sangrujee
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.